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Citrullination is the post-translational conversion of an arginine residue within a protein to the 
non-coded amino acid citrulline1. This modification leads to the loss of a positive charge and 
reduction in hydrogen bonding ability. It is carried out by a small family of tissue-specific 
vertebrate enzymes called peptidylarginine deiminases (PADIs)2 and is associated with the 
development of diverse pathological states such as autoimmunity, cancer, neurodegenerative 
disorders, prion diseases and thrombosis2,3. Nonetheless, the physiological functions of 
citrullination remain ill-defined, though citrullination of core histones has been linked to 
transcriptional regulation and the DNA damage response4–8. PADI4 (or PAD4/PADV), the only 
PADI with a nuclear localization signal9, was previously shown to act in myeloid cells where it 
mediates profound chromatin decondensation during the innate immune response to infection10. 
Here we show that the expression and enzymatic activity of PADI4 are also induced under 
conditions of ground state pluripotency and during reprogramming. PADI4 is part of the 
pluripotency transcriptional network, binding to regulatory elements of key stem cell genes and 
activating their expression. Its inhibition lowers the percentage of pluripotent cells in the early 
mouse embryo and significantly reduces reprogramming efficiency. Using an unbiased proteomic 
approach we identify linker histone H1 variants, which are involved in the generation of compact 
chromatin11, as novel PADI4 substrates. Citrullination of a single arginine residue within the DNA 
binding site of H1 results in its displacement from chromatin and global chromatin 
decondensation. Together, these results uncover a role for citrullination in the regulation of 
pluripotency and provide new mechanistic insights into how citrullination regulates chromatin 
compaction.
Pluripotent cells have the capacity to self-renew and differentiate into all somatic and germ 
cell lineages and, hence, possess immense therapeutic potential for a multitude of medical 
conditions. Their generation by reprogramming of differentiated somatic cells has been 
achieved by nuclear transfer, cell fusion and transduction of transcription factors, such as 
Oct4, Sox2, Klf4 and c-Myc12. Pluripotent cells have a distinctly open chromatin structure 
that is essential for unrestricted developmental potential13,14 and reprogramming involves an 
almost complete epigenetic resetting of somatic cells13. The ability of PADI4-mediated 
histone citrullination to induce chromatin decondensation in neutrophils10 prompted us to 
ask whether it can play a role in pluripotency, where chromatin decondensation is also 
necessary. To investigate this we first assessed the expression of Padi4 in the embryonic 
stem cell line ES Oct4-GIP (ES), the neural stem cell line NSO4G (NS) and in induced 
pluripotent stem (iPS) cells derived NSO4G (see Methods). Padi4 is expressed in pluripotent 
ES and iPS but not multipotent NS cells (Fig.1a). Culture of ES cells in 2i/LIF medium 
establishes a ground state of pluripotency15. This leads to the down-regulation of lineage 
specific markers and the up-regulation of pluripotency factors, as well as rapid induction of 
Padi4 (Fig. 1b). The pattern of Padi4 expression follows closely that of Nanog, an essential 
transcription factor for the transition to ground state pluripotency16(Fig 1a,b). While other 
PADIs are expressed in pluripotent cells, PADI4 is the only one whose expression clearly 
associates with naïve pluripotency (Extended Data Fig. 1a,b). Citrullination of histone H3 
(H3Cit), a modification shown previously to be carried out specifically by PADI417, is 
detectable in ES and iPS cells (Extended Data Fig. 1c), indicating that PADI4 is also 
enzymatically active. H3 and global citrullination are undetectable in NS cells (Extended 
Data Fig. 1c,d).
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To determine the kinetics of PADI4 activation during the establishment of pluripotency, we 
examined RNA and protein samples collected daily during the course of reprogramming of 
NSO4G into iPS cells16. Padi4 is rapidly induced in NS cells after transduction of 
reprogramming factors but only becomes active to citrullinate H3 after introduction of 2i/
LIF, closely following the onset of Nanog expression (Fig. 1c). These observations strongly 
suggested that PADI4 activity is associated with ground state pluripotency and prompted us 
to examine whether Padi4 is part of the pluripotency transcriptional network.
First, we asked whether the reprogramming factors regulate Padi4 expression, utilizing the 
ZHBTc4.1 and 2TS22C cell lines where Oct4 and Sox2, respectively, can be deleted acutely 
in response to doxycycline treatment (see Methods). Deletion of Oct4, but not Sox2, led to a 
decrease in Padi4 mRNA levels (Extended Data Fig. 1e). Furthermore, while Oct4 and Klf4 
occupy the Padi4 promoter in ES, but not NS cells, Sox2 is bound in both cell types 
(Extended Data Fig. 1f). To understand the effects of PADI4 on transcriptional regulation in 
pluripotent cells, we analyzed the transcriptome of ES cells upon PADI4 over-expression 
and inhibition. Several key pluripotency genes are up-regulated in response to PADI4 over-
expression (Fig. 1d, Extended Data Figure 2a and Supplementary Table 2), including Klf2, 
Tcl1, Tcfap2c, and Kit. Tcl1 was previously identified as the only regulator of self-renewal 
up-regulated in ground state pluripotency15 and over-expression of Tcl1 or Tcfap2c 
positively influence this process18. Gene Ontology (GO) analysis of this dataset indicates an 
enrichment of genes involved in stem cell development and maintenance (Fig. 1e). In 
addition, knockdown of Padi4 in mES cells leads to decreased expression of Tcl1 and 
Nanog, which is rescued by exogenous expression of RNAi-resistant human PADI4 (Fig. 1f, 
Extended Data Fig. 2b,c). These genes are under the control of PADI4 enzymatic activity 
since treatment with the chemical inhibitor Cl-amidine, which disrupts citrullination by 
PADI419, down-regulates their expression (Fig. 1g). Chromatin immunoprecipitation (ChIP) 
analysis indicated that H3Cit is present on regulatory regions of Tcl1 and Nanog in ES and 
iPS cells, but not NS cells (Fig. 1h and Extended Data Fig. 3a). Accordingly, exogenously 
expressed human PADI4 localizes to and is enzymatically active on these regions, as well as 
regulatory regions of Klf2 and Kit in ES cells (Extended Data Fig. 3b,c). In contrast to 
PADI4 over-expression, treatment of ES cells with Cl-amidine led to up-regulation of 
differentiation markers such as Prickle1, EphA1 and Wnt8a and down-regulation of 
pluripotency markers such as Klf5 (Extended Data Fig. 4a,b, and Supplementary Table 3), in 
addition to Nanog and Tcl1 (Fig. 1g). GO analysis of this dataset indicated enrichment in 
genes involved in cell differentiation (Extended Data Fig. 4c). Pou5f1 (Oct4), Klf4, Sox2 
and c-Myc, were not affected by PADI4 modulation (Extended Data Fig. 2a and 
Supplementary Tables 2 and 3). Cumulatively, the above results place PADI4 within the 
pluripotency transcriptional network, suggesting that it acts downstream of some of the 
cardinal reprogramming factors to regulate a specific subset of pluripotency genes.
Prompted by the above observations, we investigated whether PADI4 is necessary for 
pluripotency, as assessed during reprogramming (Extended Data Fig. 5a) and in the early 
stages of embryo development. NSO4G cells express a GFP reporter under the control of the 
Oct4 regulatory sequences, which is activated upon acquisition of pluripotency16, allowing 
us to trace reprogrammed cells. Knock-down of Padi4 in NSO4G-derived pre-iPS cells 
impaired the ability of the cells to establish H3Cit upon switch to 2i/LIF medium and led to 
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a clear reduction in reprogramming (Fig. 2a,b, Extended Data Fig. 5b-e and Extended Data 
time-lapse video). Consistent with this, levels of Tcl1 and Nanog were not elevated upon 
reprogramming to the same extent as in control cells (Fig. 2b and Extended Data Fig. 5f). 
Cl-amidine treatment led to a dramatic reduction of reprogramming efficiency and H3Cit 
(Fig. 2c and Extended Data Fig. 5g-i), suggesting that the catalytic activity of PADI4 is 
important for the induction of pluripotency.
Padi4 expression and H3Cit are detected in the early embryo20,21 and Padi4-null mice are 
born in lower numbers than would be expected by Mendelian inheritance22, suggesting that 
PADI4 loss affects embryonic development. To assess the role of PADI4 in early 
development, we cultured mouse embryos in Cl-amidine-containing medium from the 2-cell 
stage and throughout pre-implantation development (see Methods and Extended Data Fig. 
6a-c). Using 200µM Cl-amidine resulted in a complete developmental arrest of the embryos 
at the 8-cell stage (Extended Data Fig. 6a). We therefore used the maximum dose of Cl-
amidine that reduced H3Cit (Extended Data Fig. S6b,c) but did not induce arrest (10µM). 
This led to a reduced percentage of pluripotent Nanog-positive epiblast cells and an 
increased percentage of differentiated trophectoderm cells at the blastocyst stage (Fig. 2d,e 
and Extended Data Fig. 6d,e). Time-course analyses of the cleavage patterns and cell fate 
decisions in early embryos showed that Cl-amidine increased the number of symmetric cell 
divisions at the expense of asymmetric divisions at the 8 to 16- and 16 to 32-cell transitions 
(Fig. 2f,g). This resulted in 16-cell stage embryos with fewer inner cells (destined for 
pluripotency) and greater numbers of outer cells (destined for differentiation into 
trophectoderm, reviewed in 23) (Extended Data Fig. 6f). Treatment with another PADI4 
inhibitor, TDFA24, but not the HDAC inhibitor TSA, had similar effects (Extended Data Fig. 
7, 8). These results indicate that PADI4 activity also promotes the maintenance of 
pluripotent cells in the early mouse embryo.
To elucidate the molecular mechanisms by which PADI4 regulates pluripotency, we aimed to 
identify PADI4 substrates in the chromatin fraction of mES cells using Stable Isotope 
Labeling of Amino acids in Cell culture (SILAC) (Fig. 3a and Extended Data Fig. 9a,b). 
Among the identified PADI4 substrates were Atrx, Dnmt3b, Trim28 and variants of linker 
histone H1 (Fig. 3b-e, Extended Data Fig. S9c-f, S10 and Supplementary Table 4), all of 
which can impact pluripotency. Histone H1 stabilizes the nucleosome and facilitates 
chromatin condensation, a state that is less permissive to processes that require access to the 
DNA, such as transcription11. The identified citrullinated H1 peptides correspond to, and are 
common between, variants H1.2, H1.3 and H1.4 (Fig. 3d,e), while an additional peptide 
corresponds to the same residue in H1.5 (Extended Data Fig. 10a,b). In ES cells, H1.2, H1.3 
and H1.4 are required for chromatin compaction25, while their depletion leads to increased 
expression of pluripotency genes such as Nanog and stalls them in a self-renewal state with 
impaired differentiation capability26. Notably, H1 is more loosely bound to chromatin in ES 
cells than in differentiated cells14 and its genomic localization in cancer cells was shown to 
anti-correlate with that of PADI47.
Mass spectrometric analysis accounted for all arginine residues within H1 but indicated that 
Arg54 (H1R54) is the only site citrullinated by PADI4 (Fig. 3e and Extended Data Fig. 9c). 
Indeed, we found that while H1.2 is citrullinated in ES cells (already by endogenous PADI4, 
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and significantly increased upon PADI4 over-expression), it is refractory to modification 
when Arg54 is mutated (Fig. 3f). Similar results were obtained in in vitro citrullination 
assays (Extended Data Fig. 11a). H1R54 lies within the globular domain of H1 (Extended 
Data Fig. 11b), which is highly conserved among the linker histone family and is necessary 
for interaction with nucleosomal DNA27,28. To test whether H1R54 is necessary for binding 
of H1 to nucleosomes, we mutated and assessed it in nucleosome-binding assays. Figure 3g 
shows that an R54A mutant, which mimics the charge change that accompanies 
citrullination, is impaired for nucleosome binding. An R54K mutant, which retains the 
positive charge, is impaired to a lesser extend (Fig. 3g) suggesting that H1R54 is important 
for electrostatic interactions between H1.2 and the nucleosome.
The above results open up the possibility that PADI4 may affect chromatin compaction in 
pluripotent cells. To test this hypothesis, we first assessed whether citrullination by ectopic 
PADI4 can lead to decondensation of differentiated cell chromatin. Recombinant PADI4 was 
added to permeabilized and stabilized differentiated C2C12 mouse myoblast nuclei (Fig. 
4a). This protocol ensures stabilization of the nuclear component while allowing the free 
diffusion of non-chromatin bound nuclear proteins into the extra-nuclear fraction, and their 
collection by washing. Incubation with active PADI4 (Extended Data Fig. 12a,b), leads to 
the eviction of H1 from the chromatin and its diffusion out of the permeabilized nucleus 
(Fig. 4b). The evicted H1 is citrullinated on R54, as determined by mass spectrometry 
(Extended Data Figure 12c,d). Consistent with this, PADI4-treated cells showed evidence of 
decondensed chromatin, as determined by nuclear swelling, diffuse DAPI staining and 
increased sensitivity to micrococcal nuclease (Fig. 4c,d and Extended Data Figure 12e). 
Similar results were observed when PADI4 was over-expressed in C2C12 cells (Fig. 4e) or 
NS cells (data not shown). To monitor if PADI4 can affect H1 binding on pluripotent cell 
chromatin, we performed ChIP-qPCR analyses of H1.2 on the regulatory regions of Tcl1 
and Nanog and found that it is stabilized upon Padi4 knockdown (Fig. 4f). The ability of 
PADI4 to disrupt the binding of H1 to nucleosomal DNA provides a novel mechanistic 
example of how citrullination regulates protein function and chromatin condensation.
The work described above identifies citrullination of chromatin components by PADI4 as a 
feature of pluripotency (Fig. 4g), in addition to its previously described role in the myeloid 
lineage. One of the reasons for the restricted expression pattern of PADI4 may be the 
requirement for an open chromatin state in these cell types. The selective expression 
characteristics and the inducible nature of the catalytic activity of PADI4, suggest that it is 
under tight spatial and temporal regulation, giving it a unique status among chromatin 
modifying enzymes. As such, inappropriate PADI4 activity may have deleterious 
consequences, which may explain its activation in cancers of varying origin during 
progression to malignancy29. Indeed, citrullination is a common feature of several unrelated 
diseases, suggesting that strict regulation is likely to be a requirement for the physiological 
function of all PADIs. During review of this manuscript, Coonrod and colleagues suggested 
that PADI2, thought to be mainly cytoplasmic, can also citrullinate histones and lead to 
transcriptional activation30. This opens the intriguing possibility that other PADIs may 
mediate nuclear events in specific contexts, including in pluripotent cells. Further research 
into the function and targets of PADIs is likely to shed light into the etiology of several 
pathologies.
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Extended Data
Extended Data Figure 1: 
(a) Transcript levels for Padi1, Padi2 and Padi3 in ES, NS and iPS cells, as assessed by qRT-
PCR. Padi6 was undetectable in all three cell types. Expression normalized to endogenous 
levels of Ubiquitin (UbC). Error bars represent the standard error of the mean of three 
biological replicates.
(b) Transcript levels of Padi1, Padi2 and Padi3 in ES cells upon switch to 2i containing 
medium for one passage, as assessed by qRT-PCR. Padi6 was undetectable in both 
conditions. Expression normalized to UbC. Error bars represent the standard error of the 
mean of three biological replicates.
(c) Immunoblot analysis of H3Cit levels in ES, NS and iPS cells. Total H3 is presented as 
loading control.
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(d) Immunoblot analysis of total citrullination the levels in ES, NS and iPS cells, using an 
antibody against Modified Citrulline (ModCit) which recognizes peptidylcitrulline 
irrespective of amino acid sequence. Total H3 is presented as loading control.
(e) ZHBTc4.1 and 2TS22C ES cell lines were treated with 1µg/ml doxycycline for 48 hours, 
resulting in depletion of Oct4 or Sox2 (data not shown). Padi4 mRNA was significantly 
reduced upon Oct4, but not Sox2 knockdown, as assessed by qPCR. Error bars represent 
standard error of the mean of four biological replicates.
(f) ChIP-qPCR for Oct4, Sox2, Klf4, RNA polymerase II (PolII), H3K4me3 and H2A on the 
promoter of Padi4 in mES and NS cells. For each cell condition, the signal is presented as 
fold enrichment over Input and after subtracting background signal from the beads. Error 
bars represent the standard deviation of three technical qPCR replicates.
Asterisks denote difference with ES cells (a) or media (b), and 0h time point (e); - not 
significant, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 by ANOVA (a) or t-test (b,e).
Extended Data Figure 2: 
(a) Validation of selected targets from the PADI4 over-expression microarray dataset by 
qRT-PCR. Expression of Pou5f1, Sox2, Klf4 and c-Myc is not affected by PADI4 over-
expression. Expression normalised to UbC. Error bars presented as standard error of the 
mean of three biological replicates.
(b) Transcript levels of mouse Padi4 and human PADI4 in mES cells after transient knock-
down with Padi4 or control (Ctrl) shRNA, and over-expression of human PADI4 or control 
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vector (pPB CTRL), as assessed by qRT-PCR. Expression normalized to UbC. Error bars 
represent the standard error of the mean of three biological replicates.
(c) Transcript levels of mouse Padi4, Tcl1 and Nanog in mES cell clones stably expressing 
Padi4 or control (Ctrl) shRNA, as assessed by qRT-PCR. Expression normalized to UbC. 
Error bars represent the standard error of the mean of three biological replicates.
Asterisks denote difference with Ctrl (a,b,c) and between samples (b); - not significant, * 
P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 by ANOVA (b) or t-test (a,c).
Extended Data Figure 3: 
(a) Representative ChIP-qPCR for H2A on regulatory regions of Tcl1 and Nanog in mES, 
NS and iPS cells (corresponding to Fig. 1h). For each cell condition, the signal is presented 
as fold enrichment over Input and after subtracting background signal from the beads. Error 
bars represent the standard deviation of three technical qPCR replicates.
(b) ChIP-qPCR for hPADI4 on regulatory regions of Tcl1, Nanog, Klf2 and Kit, which are 
up-regulated by hPADI4 over-expression, in mES cells stably expressing hPADI4. For each 
cell condition, the signal is presented as fold enrichment over Input and after subtracting 
background signal from the beads. Error bars represent the standard deviation of three 
technical qPCR replicates.
(c) Representative ChIP-qPCR for H3Cit on regulatory regions of Tcl1 and Nanog in mES 
cells stably expressing hPADI4 and treated with 200μM Cl-amidine for 48h. For each cell 
condition, the signal is presented as fold enrichment over Input and after subtracting 
background signal from the beads. Error bars represent the standard deviation of three 
technical qPCR replicates.
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Extended Data Figure 4: 
(a) Heat map of the top 70 genes that showed differential expression after PADI4 inhibition 
in ES cells by with 200μM Cl-amidine for 48h, as determined by microarray analysis. 
Displayed values are normalized log intensities, minus the mean expression of the gene 
across the two samples. Hierarchical clustering based on correlation.
(b) Validation of selected targets from the above microarray dataset by qRT-PCR. 
Expression normalised to UbC. Error bars presented as standard error of the mean of three 
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biological replicates. Asterisks denote difference with Ctrl; - not significant, * P≤0.05, ** 
P≤0.01, *** P≤0.001, **** P≤0.0001 by t-test.
(c) Gene Ontology for Biological Process (GOBP) analysis for the most regulated gene 
categories within the microarray dataset of Cl-amidine treatment in mES cells. P-value is 
corrected for multiple testing using Benjamini and Hochberg FDR.
Extended Data Figure 5: 
(a) Scheme of reprogramming of neural stem cells to pluripotent state. NSO4G cells were 
retrovirally transduced with Oct4, Klf4 and c-Myc. After 6 days, partially reprogrammed 
pre-iPS cells arose. For shRNA experiments, pre-iPS cells were stably transfected with Ctrl 
or PADI4 shRNA and then full reprogramming was performed in the presence of 2iLIF 
media for 8 days. For PADI4 enzymatic inhibition, pre-iPS cells were immediately changed 
to 2iLIF media in the presence of the inhibitor Cl-amidine for 8 days.
(b) Quantification of flow cytometry analysis for the assessment of Oct4-GFP reporter 
expression in a reprogramming assay using pre-iPS cells stably expressing Padi4 shRNA #4 
and Ctrl shRNA. Error bars represent standard error of the mean of triplicate samples within 
a representative from four reprogramming experiments.
(c) Quantification of Oct4-GFP positive colonies in the reprogramming assay where pre-iPS 
cells were Padi4 shRNA #4 versus control (see Fig. 2a), after time-lapse image acquisition 
with Biostation CT. Error bars represent standard error of the mean of triplicate samples 
within a representative reprogramming experiment. Time-lapse video in supplementary data 
online.
(d) Immunoblot analysis of H3Cit in pre-iPS cells treated with 2i, after Padi4 knock-down 
(PADI4 shRNA #4) versus control cells (Ctrl shRNA). 2i-containing medium was added on 
day 2. Total histone H3 presented as loading control.
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(e) Quantification of flow cytometry analysis for the assessment of Oct4-GFP reporter 
expression in a reprogramming assay using pre-iPS cells stably expressing Padi4 shRNA #3 
and Ctrl shRNA. Error bars represent standard error of the mean of triplicate samples.
(f) qRT-PCR analysis for the expression of Tcl, Nanog and Padi4 mRNAs at the end of the 
above reprogramming assay (e). Error bars represent standard error of the mean of triplicate 
samples.
(g) Quantification of flow cytometry analysis for the assessment of Oct4-GFP reporter 
expression in a reprogramming assay were treated with 200μM Cl-amidine. Error bars 
represent standard error of the mean of triplicate samples within a representative from three 
reprogramming experiment.
(h) Quantification of Oct4-GFP positive colonies in the reprogramming assay where pre-iPS 
cells were treated with 200μM Cl-amidine (see Fig. 2c) after time-lapse image acquisition 
with Biostation CT. Error bars represent standard error of the mean of triplicate samples 
within a representative reprogramming experiment.
(i) Immunoblot analysis for the presence of H3Cit at the end of the above reprogramming 
assay (g). Total histone H3 presented as loading control.
Asterisks denote difference with Control; - not significant, * P≤0.05, ** P≤0.01, *** 
P≤0.001, **** P≤0.0001 by t-test
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Extended Data Figure 6: 
(a) Embryos at 2-cell stage were treated with 200µM Cl-amidine and snapshots were taken 
at E3.0, E3.5 and E4.0. 200μM Cl-amidine embryos arrested at 8-cell stage, while Control 
embryos continued development to form blastocysts. Phase contrast images are shown.
(b) Embryos at 2-cell stage were treated with 10µM Cl-amidine for 12 hours, fixed and 
stained for H3Cit at the 4-cell stage. Phase contrast, H3Cit (white) and HOECHST 33342 
(blue) images are shown. Bar represents 20µm.
(c) Embryos at E3.5 were treated with 10µM Cl-amidine for 24 hours, fixed and stained for 
H3Cit at E4.5. H3Cit (green) and HOECHST 33342 (blue) images are shown. Bar represents 
20µm.
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(d) Table with quantifications of lineage commitment in E4.5 blastocysts treated with 10µM 
Cl-amidine from the 2-cell stage. Asterisks denote difference with Control, unpaired t-test, * 
= p<0.05. n=3 (50 embryos).
(e) Embryos were cultured in medium supplemented with 10µM Cl-amidine from 2-cell 
stage and through preimplantation development. E4.5 blastocysts were fixed and stained for 
SOX17 (primitive endoderm marker, red), Cdx2 (trophectoderm marker, green) and 
HOECHST 33342 (blue). Bar represents 20µm.
(f) Time-lapse analysis of distribution of inner and outer cells at the 8 to 16-cell transition, 
upon culturing of embryos with medium containing 10µM Cl-amidine from 2-cell stage. 
Error bars represent standard error of the mean. Statistical significance was determined by 
unpaired t-test or Mann Whitney test upon non-normal distribution. Asterisks denote 
difference with Control; * P≤0.05.
Extended Data Figure 7: 
(a) Embryos at 2-cell stage were treated with 100µM TDFA for 12 hours and fixed and 
stained for H3Cit at 4-cell stage. H3Cit and HOECHST 33342 images are shown.
(b) Table representing the percentage of cells committed to each embryonic lineage in E4.5 
blastocysts upon treatment of embryos at 2-cell stage with 100µM TDFA. Bars represent 
mean percentage (±SEM). Asterisks denote difference with Control, Mann-Whitney test, * = 
p<0.05. n=3 (60 embryos).
(c) Embryos at 2-cell stage were treated with 100µM TDFA and fixed at embryonic day 
E4.5. Phase contrast, Nanog (green), Sox17 (purple), Cdx2 (red) and HOECHST 33342 
(blue) images are shown.
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Extended Data Figure 8: 
(a) Embryos at 2-cell stage were treated with 10nM TSA for 12 hours, and fixed and stained 
for H3K9ac at 4-cell stage. H3K9ac and HOECHST 33342 images are shown.
(b) Table representing the percentage of cells committed to each embryonic lineage in E4.5 
blastocysts upon treatment of embryos at 2-cell stage with 10nM TSA. Bars represent mean 
percentage (±SEM). Asterisks denote difference with Control, unpaired t-test, * = p<0.05. 
n=2 (32 embryos).
(c) Embryos at 2-cell stage were treated with 10nM TSA and fixed at embryonic day E4.5. 
Phase contrast, Nanog (green), Sox17 (purple), Cdx2 (red) and HOECHST 33342 (blue) 
images are shown.
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Extended Data Figure 9: 
(a) Histogram demonstrating the mass accuracies of all fragment ion masses used for 
identifying citrullinated peptides in our HCD MS/MS spectra. >490.000 y- and b-ion masses 
are depicted. The average absolute mass accuracy for all of these fragment ions is 3.97 ppm.
(b) Scatter plot representing SILAC ratios in ES cells cultured in 13C6 L-Lysine (HEAVY) 
and LIGHT medium separately, to assess extend and quality of SILAC labeling. No 
significant outliers are observed, indicating equal labeling.
(c) Peptide coverage of histone H1 by LC-MS analysis. Detected peptides are highlighted in 
light green and cover >60% of H1. While all arginine residues of Histone H1 (highlighted in 
dark green) were accounted for by the analysis, Arg54 was the only one found citrullinated.
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(d) Fragmentation spectra of the unmodified LysC peptide ERSGVSLAALKK surrounding 
Arginine 54 of H1.2 (unmodified counterpart of citrullinated peptide depicted in Fig. 3d). 
The y and b series indicate fragments at amide bonds of the peptide.
(e) Fragment ion table (expected and observed masses for detected y and b ions) for the 
identified H1R54 citrullination of peptide ERSGVSLAALKK on histone H1.2 (as shown in 
Fig. 3d). All measured fragment ions were detected with mass accuracies <10ppm, 
unambiguously identifying that the detected peptide sequence harbors a citrullination at 
position R54.
(f) Theoretical and measured b- and y-ion fragment masses for the corresponding 
unmodified and heavy SILAC labeled H1.2 peptide, as presented in (d) above.
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Extended Data Figure 10: 
(a) MS spectrum of Histone H1.5 in a SILAC proteomic screen for identification of PADI4 
substrates. Linker histone H1.5 is deiminated by PADI4, as identified by a highly increased 
SILAC ratio of the heavy labeled identified peptide (marked by a red dot).
(b) Fragmentation spectra of the doubly charged LysC peptide ERGGVSLPALK 
surrounding Arginine 54 of H1.5. The y and b series indicate fragments at amide bonds of 
the peptide, unambiguously verifying the citrullinated peptide.
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Extended Data Figure 11: 
(a) Mutation of R54 renders histone H1.2 refractory to deimination. Immunoblot analysis of 
recombinant histone H1.2 using an antibody that detects all deimination events (ModCit). 
Wild type and R54-mutant H1.2 were treated with recombinant PADI4, in the presence of 
activating calcium. Only wild-type H1.2 can be deiminated, indicating that R54 is the only 
substrate of PADI4 in H1.2. No-calcium reactions presented as negative controls. Total H1.2 
presented as loading control.
(b) Schematic representation of the position of R54 within the globular domain linker 
histone H1.2.
Extended Data Figure 12: 
(a) Immunoblot analysis of the “Pellet” fraction of C2C12 permeabilised cells treated with 
recombinant PADI4. Presence of H3Cit species indicates PADI4 activity. Total H3 is 
presented as a control for equal use of starting material in the two experimental conditions.
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(b) Immunofluorescence analysis of C2C12 nuclei after treatment with recombinant PADI4. 
Presence of H3Cit species indicates PADI4 activity. DNA is visualised by staining with 
DAPI.
(c) Fragmentation spectra of the citrullination site R54 on the evicted H1.2 peptide 
ERSGVSLAALK (corresponding to Fig. 4b). The evicted Histone H1 is citrulinated at R54.
(d) Theoretical and measured b- and y-ion fragment masses for the citrullinated H1.2 
peptide (peptide sequence ERSGVSLAALK) evicted after treatment of C2C12 cells with 
recombinant hPADI4 (corresponding to Fig. 4b).
(e) Micrococcal nuclease digestion of C2C12 nuclei after treatment with recombinant 
PADI4, as described in Fig. 4a. M= size marker.
Supplemental Information
Refer to Web version on PubMed Central for supplementary material.
Acknlowledgements
This work was funded by programme grants from Cancer Research UK (T.K.) and EMBL (P.B., R.L.). R.P.H-S and 
JBG are supported by the Medical Research Council [G1001690] and the Wellcome Trust. G.C.-B. was funded by 
EMBO (Long-Term Post-Doctoral Fellowship), European Union (FP7 Marie Curie Intra-European Fellowship for 
Career Development) and Swedish Research Council. M.A.C was funded by an EMBO Long-Term Post-Doctoral 
Fellowship and a Human Frontier Science Programme Long-Term Post-Doctoral Fellowship. C.S.O was supported 
by FAPESP (Foundation for Research Support of the State of São Paulo) and mouse embryo work was supported by 
the Wellcome Trust programme grant to M.Z.G. M.L.N was partly supported by the Novo Nordisk Foundation 
Center for Protein Research, the Lundbeck Foundation, and by and the European Commission’s 7th Framework 
Programme HEALTH-F7-2010-242129/SYBOSS. We would like to thank Sri Lestari, Alistair Cook and Cynthia 
Hill for technical assistance; Paul Thompson for kindly providing the TDFA compound; GSK Epinova for Cl-
amidine; Till Bartke for the kind gift of histone octamers and help with nucleosome pull-down assays; Andrew 
Finch for help with FPLC chromatography; Agnieszka Jedrusik for help with embryo work; Rachael Walker at the 
Flow Cytometry Core Facility at Wellcome Trust Centre for Stem Cell Research, University of Cambridge and Thor 
Theunissen for help with the flow cytometry; and members of the Kouzarides laboratory for critical discussions of 
the work. 2TS22C cells were kindly provided by Dr. Hitoshi Niwa, at the RIKEN Center for Developmental 
Biology, Kobe, Japan. The ChIP grade H1.2 antibody was a generous gift from Prof. Arthur Skoultchi, Albert 
Einstein School of Medicine, New York, USA.
References
1. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating 
enzymes: genes, features and involvement in disease. BioEssays: news and reviews in molecular, 
cellular and developmental biology. 2003; 25:1106–1118. DOI: 10.1002/bies.10357
2. Wang S, Wang Y. Peptidylarginine deiminases in citrullination, gene regulation, health and 
pathogenesis. Biochim Biophys Acta. 2013; 1829:1126–1135. DOI: 10.1016/j.bbagrm.2013.07.003 
[PubMed: 23860259] 
3. Martinod K, et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for 
deep vein thrombosis in mice. Proc Natl Acad Sci U S A. 2013; 110:8674–8679. DOI: 10.1073/
pnas.1301059110 [PubMed: 23650392] 
4. Hagiwara T, Nakashima K, Hirano H, Senshu T, Yamada M. Deimination of arginine residues in 
nucleophosmin/B23 and histones in HL-60 granulocytes. Biochemical and biophysical research 
communications. 2002; 290:979–983. DOI: 10.1006/bbrc.2001.6303 [PubMed: 11798170] 
5. Cuthbert GL, et al. Histone deimination antagonizes arginine methylation. Cell. 2004; 118:545–553. 
DOI: 10.1016/j.cell.2004.08.020 [PubMed: 15339660] 
6. Wang Y, et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. 
Science. 2004; 306:279–283. DOI: 10.1126/science.1101400 [PubMed: 15345777] 
Christophorou et al. Page 19
Nature. Author manuscript; available in PMC 2016 April 25.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
7. Zhang X, et al. Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos 
expression in breast cancer cells. PLoS genetics. 2011; 7:e1002112.doi: 10.1371/journal.pgen.
1002112 [PubMed: 21655091] 
8. Tanikawa C, et al. Regulation of histone modification and chromatin structure by the p53-PADI4 
pathway. Nature communications. 2012; 3:676.doi: 10.1038/ncomms1676
9. Asaga H, Nakashima K, Senshu T, Ishigami A, Yamada M. Immunocytochemical localization of 
peptidylarginine deiminase in human eosinophils and neutrophils. Journal of leukocyte biology. 
2001; 70:46–51. [PubMed: 11435484] 
10. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflammatory stimuli in 
neutrophils. J Immunol. 2008; 180:1895–1902. [PubMed: 18209087] 
11. Buttinelli M, Panetta G, Rhodes D, Travers A. The role of histone H1 in chromatin condensation 
and transcriptional repression. Genetica. 1999; 106:117–124. [PubMed: 10710717] 
12. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature. 
2010; 465:704–712. DOI: 10.1038/nature09229 [PubMed: 20535199] 
13. Gaspar-Maia A, Alajem A, Meshorer E, Ramalho-Santos M. Open chromatin in pluripotency and 
reprogramming. Nature reviews. Molecular cell biology. 2011; 12:36–47. DOI: 10.1038/nrm3036 
[PubMed: 21179060] 
14. Meshorer E, et al. Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem 
cells. Dev Cell. 2006; 10:105–116. DOI: 10.1016/j.devcel.2005.10.017 [PubMed: 16399082] 
15. Marks H, et al. The Transcriptional and Epigenomic Foundations of Ground State Pluripotency. 
Cell. 2012; 149:590–604. DOI: 10.1016/j.cell.2012.03.026 [PubMed: 22541430] 
16. Theunissen TW, et al. Nanog overcomes reprogramming barriers and induces pluripotency in 
minimal conditions. Curr Biol. 2011; 21:65–71. DOI: 10.1016/j.cub.2010.11.074 [PubMed: 
21194951] 
17. Darrah E, Rosen A, Giles JT, Andrade F. Peptidylarginine deiminase 2, 3 and 4 have distinct 
specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid 
arthritis. Annals of the rheumatic diseases. 2012; 71:92–98. DOI: 10.1136/ard.2011.151712 
[PubMed: 21859690] 
18. Polo JM, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 2012; 
151:1617–1632. DOI: 10.1016/j.cell.2012.11.039 [PubMed: 23260147] 
19. Luo Y, et al. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural 
characterization. Biochemistry. 2006; 45:11727–11736. DOI: 10.1021/bi061180d [PubMed: 
17002273] 
20. Brahmajosyula M, Miyake M. Localization and expression of peptidylarginine deiminase 4 (PAD4) 
in mammalian oocytes and preimplantation embryos. Zygote. 2011; :1–11. DOI: 10.1017/
S0967199411000633
21. Kan R, et al. Potential role for PADI-mediated histone citrullination in preimplantation 
development. BMC developmental biology. 2012; 12:19.doi: 10.1186/1471-213X-12-19 [PubMed: 
22712504] 
22. Li P, et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular 
traps. J Exp Med. 2010; 207:1853–1862. DOI: 10.1084/jem.20100239 [PubMed: 20733033] 
23. Zernicka-Goetz M, Morris SA, Bruce AW. Making a firm decision: multifaceted regulation of cell 
fate in the early mouse embryo. Nat Rev Genet. 2009; 10:467–477. DOI: 10.1038/nrg2564 
[PubMed: 19536196] 
24. Jones JE, et al. Synthesis and screening of a haloacetamidine containing library to identify PAD4 
selective inhibitors. ACS chemical biology. 2012; 7:160–165. DOI: 10.1021/cb200258q [PubMed: 
22004374] 
25. Fan Y, et al. Histone H1 depletion in mammals alters global chromatin structure but causes specific 
changes in gene regulation. Cell. 2005; 123:1199–1212. DOI: 10.1016/j.cell.2005.10.028 
[PubMed: 16377562] 
26. Zhang Y, et al. Histone h1 depletion impairs embryonic stem cell differentiation. PLoS genetics. 
2012; 8:e1002691.doi: 10.1371/journal.pgen.1002691 [PubMed: 22589736] 
27. Goytisolo FA, et al. Identification of two DNA-binding sites on the globular domain of histone H5. 
EMBO J. 1996; 15:3421–3429. [PubMed: 8670844] 
Christophorou et al. Page 20
Nature. Author manuscript; available in PMC 2016 April 25.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
28. Brown DT, Izard T, Misteli T. Mapping the interaction surface of linker histone H1(0) with the 
nucleosome of native chromatin in vivo. Nat Struct Mol Biol. 2006; 13:250–255. DOI: 10.1038/
nsmb1050 [PubMed: 16462749] 
29. Chang X, et al. Increased PADI4 expression in blood and tissues of patients with malignant tumors. 
BMC cancer. 2009; 9:40.doi: 10.1186/1471-2407-9-40 [PubMed: 19183436] 
30. Zhang X, et al. Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination 
facilitates estrogen receptor alpha target gene activation. Proc Natl Acad Sci U S A. 2012; 
109:13331–13336. DOI: 10.1073/pnas.1203280109 [PubMed: 22853951] 
Christophorou et al. Page 21
Nature. Author manuscript; available in PMC 2016 April 25.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1: PADI4 expression and activity are features of pluripotent cells
(a,b) qRT-PCR for Padi4 and Nanog expression in ES, NS and iPS cells (a), and in ES cells 
upon culture in 2i/LIF for one passage (b). Pou5f1, Olig2 and Pax6 are presented as 
controls. Expression normalized to Ubiquitin (UbC). Error bars: standard error of the mean 
of three biological replicates.
(c) qRT-PCR for Padi4 and Nanog expression and H3Cit immunoblot during the course of 
reprogramming (see also Extended Data Fig. 5a). Loading control: total histone H3. 
Representative of four experiments.
(d) Heat map of the genes regulated upon hPADI4 over-expression in mES cells, as 
determined by microarray analysis. Displayed values are normalized log intensities, minus 
the mean expression of the gene across the four samples. Hierarchical clustering based on 
correlation.
(e) Gene Ontology for Biological Process (GOBP) analysis of the above microarray dataset. 
P- value is corrected for multiple testing using Benjamini and Hochberg False Discovery 
Rate (FDR).
(f,g) qRT-PCR for Tcl1 and Nanog expression in mES cells after transient knock-down with 
Padi4 or control (Ctrl) shRNAs, and over-expression of human PADI4 or control vector 
(pPB CTRL) (f), and after treatment with 200µM Cl-amidine (g). Expression normalized to 
UbC. Error bars: standard error of the mean of three biological replicates.
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(h) ChIP-qPCR for H3Cit on regulatory regions of Tcl1 and Nanog in mES, NS and iPS 
cells. Error bars: standard deviation of three technical qPCR replicates. Representative of 
three experiments.
Asterisks denote difference with ES cells (a) or media (b), Control (f, g) and between 
samples (f); - not significant, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001, by 
ANOVA (a,f) or t-test (b,g).
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Figure 2: Citrullination and PADI4 regulate pluripotency during reprogramming and early 
embryo development
(a) Flow cytometry analysis and phase contrast/fluorescence images for the assessment of 
Oct4-GFP reporter expression after reprogramming of pre-iPS cells stably expressing Padi4 
and Ctrl shRNAs. Representative of four independent experiments. Time-lapse video in 
supplementary data online.
(b) qRT-PCR for expression of Tcl1, Nanog and Padi4 at the end of the above 
reprogramming assay. Error bars: standard error of the mean of triplicate samples.
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(c) Flow cytometry analysis and phase contrast/fluorescence images for the assessment of 
Oct4-GFP reporter expression after reprogramming assay of pre-iPS cells treated with 
200µM Cl-amidine. Representative of three independent experiments.
(d) E4.5 blastocysts from 2-cell stage embryos treated with 10µM Cl-amidine. SOX17 
(primitive endoderm marker, red), Cdx2 (trophectoderm marker, green), Nanog (epiblast 
marker, white) and HOECHST 33342 (blue).
(e) Distribution of inner cell mass versus trophectoderm cells in E3.5 blastocyst treated as 
above.
(f,g) Time-lapse analysis of embryos in 10µM Cl-amidine from 2-cell stage. Number of 
symmetric versus asymmetric divisions at the 8 to 16-cell transition (f) and type of divisions 
at the 16 to 32-cell transition (g). Error bars: standard error of the mean.
Statistical significance was determined by unpaired t-test (b), or Mann Whitney test upon 
non-normal distribution (e-g). Asterisks denote difference with Control; - not significant, * 
P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001.
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Figure 3: PADI4 citrullinates Arg54 on linker histone H1 and affects its binding to nucleosomal 
DNA
(a) Experimental strategy for screening for PADI4 citrullination substrates in the chromatin 
fraction of ES cells.
(b) Scatter plot representing the overall fold change for all identified citrullination sites. Red 
diamonds: PADI4-regulated citrullinations.
(c) Table representing the 40 most highly regulated PADI4 substrates, their individual 
citrullination sites and the log2 SILAC ratio. Complete dataset in Supplementary Table 4.
(d) Quantification of citrullination site R54 on H1.2 through differential regulation of the 
triply charged peptide ERSGVSLAALKK.
(e) Fragmentation spectra of the triply charged and heavy SILAC labeled LysC peptide 
ERSGVSLAALKK surrounding Arginine 54 of H1.2. The y and b series indicate fragments 
at amide bonds of the peptide.
(f) Citrullination immunoblot of wild-type and R54A mutant GFP-tagged H1.2 expressed 
and pulled-down from ES cells expressing PADI4 or control vector (Mock). Control for the 
efficiency of the pull-down: GFP.
(g) Nucleosome pull-down assay using wild-type and R54-mutant H1.2. WB: Western Blot.
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Figure 4: PADI4 evicts histone H1 from chromatin and affects chromatin condensation
(a) Schematic representation of treatment of C2C12 myoblast nuclei with recombinant 
PADI4.
(b) Immunoblot analysis of the wash fraction after the above treatment, for histone H1.2.
(c,d) Quantification of nuclear volume (c) and representative DAPI fluorescence (d) upon 
treatment of permeabilized C2C12 nuclei with recombinant PADI4. Error bars: standard 
error of the mean. Statistical significance determined by unpaired student t-test.
(e) Micrococcal nuclease digestion of C2C12 cells overexpressing an empty vector (Mock) 
or hPADI4.
(f) ChIP-qPCR for H1.2 on the regulatory regions of Tcl1 and Nanog in mES cells stably 
expressing Padi4 or Ctrl shRNA. Error bars: standard error of the mean of three technical 
qPCR replicates. Representative of two experiments.
(g) Proposed model for the role of PADI4 in the regulation of pluripotency.
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